Duality Advisers LP Has $1.28 Million Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Duality Advisers LP raised its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 32.7% in the fourth quarter, Holdings Channel reports. The fund owned 29,432 shares of the life sciences company’s stock after acquiring an additional 7,252 shares during the period. Duality Advisers LP’s holdings in Integra LifeSciences were worth $1,282,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Handelsbanken Fonder AB grew its stake in Integra LifeSciences by 32.3% in the fourth quarter. Handelsbanken Fonder AB now owns 12,302 shares of the life sciences company’s stock valued at $536,000 after acquiring an additional 3,000 shares during the period. Signaturefd LLC grew its stake in Integra LifeSciences by 248.5% in the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after acquiring an additional 415 shares during the period. Cooke & Bieler LP grew its stake in Integra LifeSciences by 4.4% in the fourth quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock valued at $123,447,000 after acquiring an additional 120,410 shares during the period. Louisiana State Employees Retirement System bought a new stake in shares of Integra LifeSciences in the fourth quarter valued at about $832,000. Finally, Cardinal Capital Management lifted its holdings in shares of Integra LifeSciences by 1.6% in the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after purchasing an additional 347 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $29.38 on Wednesday. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. The stock’s 50 day moving average price is $36.28 and its two-hundred day moving average price is $38.97. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of 35.40, a P/E/G ratio of 0.87 and a beta of 1.12. Integra LifeSciences Holdings Co. has a 12-month low of $27.85 and a 12-month high of $59.10.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm had revenue of $397.00 million during the quarter, compared to analyst estimates of $399.30 million. During the same period in the previous year, the company posted $0.94 EPS. Integra LifeSciences’s revenue for the quarter was down .3% compared to the same quarter last year. On average, analysts anticipate that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. JMP Securities dropped their target price on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Truist Financial dropped their target price on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. Finally, Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective on the stock in a research note on Wednesday, April 3rd. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $44.89.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.